5560-77-0

Usage

Uses

Used in Pharmaceutical Industry:
Rotoxamine is used as an antihistaminic agent for the treatment of allergic reactions and symptoms. It works by blocking the action of histamine, a substance released by the body during an allergic response, which causes itching, redness, and swelling. By inhibiting histamine's effects, Rotoxamine helps alleviate the discomfort associated with allergies.
Used in Allergy Treatment:
Rotoxamine is used as a therapeutic agent for the management of allergic conditions such as rhinitis, urticaria, and angioedema. It is particularly effective in reducing the symptoms of seasonal allergies, including sneezing, runny nose, and itchy eyes, by counteracting the histamine-induced inflammation.
Used in Sleep Aid Formulations:
Rotoxamine is also used as an ingredient in sleep aid formulations due to its sedative properties. It helps promote relaxation and drowsiness, making it easier for individuals to fall asleep and stay asleep throughout the night.

InChI:InChI=1/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3/t16-/m0/s1

Upstream product

• 182009-51-4 2-[(S)-(4-Chloro-phenyl)-pyridin-2-yl-methoxy]-N,N-dimethyl-acetamide 
• 100-70-9 2-Cyanopyridine 
• 6318-51-0 2-(4-chlorobenzoyl)pyridine 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 176022-47-2 (S)-(+)-(4-chlorophenyl)-(2-pyridyl)methanol 
• 486-16-8 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethylethanamine 
• 1563017-46-8 (4-chlorophenyl)(1-oxido-2-pyridinyl)methanone 
• 107-99-3 2-(dimethylamino)ethyl chloride 

Relevant academic research and scientific papers

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

Asymmetric synthesis method for anti-allergy drug carbinoxamine

The invention relates to an asymmetric synthesis method for an anti-allergy drug carbinoxamine. The method specifically comprises the following steps: oxidizing (4-chlorophenyl)(2-pyridyl)ketone to obtain (4-chlorophenyl)(2-pyridyl)ketone-N-oxide; by taking monosulfonylated chiral diamine and metal ruthenium/rhodium/iridium complex as catalysts and sodium formate or a formic acid and triethylamine mixture or isopropanol as a hydrogen source, reducing the (4-chlorophenyl)(2-pyridyl)ketone-N-oxide through asymmetry transfer hydrogenation to prepare (S)-(4-chlorophenyl)(2-pyridyl)methanol-N-oxide; reducing the (S)-(4-chlorophenyl)(2-pyridyl)methanol-N-oxide to obtain (S)-(4-chlorophenyl)(2-pyridyl)methanol; and performing etherification reaction on the (S)-(4-chlorophenyl)(2-pyridyl)methanol and 2-chloro-N,N-dimethylethylamine to obtain the product, wherein the overall yield is 74.6%.

Asymmetric synthesis of (S)-carbinoxamine. New aspects of oxazaborolidine-catalyzed enantioselective carbonyl reduction

A new process has been developed for the highly enantioselective catalytic reduction of 2-aroylpyridines and successfully applied to the synthesis of (S)-carbinoxamine (1), a therapeutically important histamine H1 antagonist. Related enantioselective reductions of 4-aroylpyridines and ortho-substituted benzophenones are also described.